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Fertility issues are common amongst women with rheumatoid arthritis (RA). Interleukin 6
(IL-6) and tumor necrosis factor alpha (TNFα), known key players in RA pathogenesis, have
been associated with reproductive disorders. This study investigates the role of these
cytokines in decreased fertility in women with active RA. Preconception cytokine
measurements of 61 patients from the PARA-cohort, a prospective study on RA and
pregnancy, were studied in relation to time to pregnancy as a measure for fertility. IL-6
levels were higher in patients with a time to pregnancy longer than 1 year (p  0.016).
Survival analysis of patients stratified by high or low serum IL-6 levels, shows a prolonged
time to pregnancy in the high IL-6 group (p  0.045). Univariate cox regression analysis of
IL-6 in relation to time to pregnancy as well as multivariate cox regression analysis
correcting for age, disease activity, nulliparity, NSAID use and prednisone use were
performed, with hazards ratios for log transformed IL-6 of 0.68 (95% CI: 0.51–0.93,
p  0.015) and 0.66 (95%CI: 0.43–0.99, p  0.044), respectively. For TNFα, no association
with time to pregnancy was found. This study shows that high IL-6, but not TNFα, is
associated with decreased fertility in women with RA. This finding provides a rationale to
therapeutically target the IL-6 pathway in the time period before pregnancy. More research
in the form of large cohort studies on drug safety and the effect of bDMARDS on fertility is
needed for implementation of treatment strategies directed at fertility issues in women
with RA.
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INTRODUCTION
During reproductive age, rheumatoid arthritis (RA) is one of the most common chronic diseases.
Female patients with RA have more difficulty conceiving a child, reflected by higher subfertility
rates, longer time to pregnancy and decreased family size (Smeele and Dolhain, 2019).
Subfertility, defined as a time to pregnancy of greater than 12 months, is related to disease
activity in RA patients (Brouwer et al., 2015). Therefore, underlying immunological pathogenic
factors associated with active disease are thought to be involved. To date, immunologic
mechanisms causing subfertility in RA patients remain unresolved. Identifying which factors
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Two well-known factors contributing to RA pathogenesis are
interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFα)
(Yoshida and Tanaka, 2014; Smolen et al., 2016). In normal
physiology, IL-6 and TNFα both act as mediators of the acute
phase response. In RA, persistent expression of IL-6 contributes
to synovial inflammation and damage and is involved in T-cell
migration and activation (Tanaka et al., 2014; McInnes and
Schett, 2017). Dysregulation of TNFα in RA plays a major role
in synovial proliferation and the pro-inflammatory signaling
cascade in the joint. Therapies targeting the IL-6 receptor and
TNFα are effective treatment options for RA patients (Taylor and
Feldmann, 2009; Kang et al., 2019).
Next to their roles in RA pathogenesis, IL-6 and TNFα play a
role in reproduction physiology. Dysregulation of IL-6, up or
down, may impair fertility and harm pregnancy (Markert et al.,
2011). IL-6 has been described to play a role in several
inflammatory disorders of the female reproductive organs. For
example in endometriosis, serum IL-6 levels are increased in
patients and high levels of IL-6 in peritoneal fluid are linked to
infertility (Wang F. et al., 2018;Wang X.M. et al., 2018). Likewise,
in polycystic ovary syndrome (PCOS), IL-6 levels are higher than
in matched controls and a positive correlation between high
circulating IL-6 levels and androgen status was described (Peng
et al., 2016). Moreover, serum IL-6 levels are higher in women
with unexplained infertility (Demir et al., 2009). To a lesser
extent, similar associations for TNFα and reproductive
disorders are reported: like IL-6, TNFα is increased in
endometriosis and PCOS patients (Iwabe et al., 2002; Wu and
Ho, 2003; Ebejer and Calleja-Agius, 2013).
The roles of IL-6 and TNFα in subfertility of RA patients are
yet unknown. Unraveling the role of these cytokines in subfertile
RA patients might open the door to new treatment strategies.
Taking above-stated information into account, we hypothesize
that high levels of circulating IL-6 and TNFα in women with
active RA contribute to subfertility in these patients.
METHODS
Study Population
This study is embedded in the Pregnancy-induced Amelioration
of RA (PARA) study, a prospective nationwide cohort of
pregnant women with RA in the Netherlands (2002–2010)
that previously has been extensively described in literature (de
Man et al., 2008). Patients fulfilling the 1987 American College of
Rheumatology criteria for RA (Arnett et al., 1988) with a wish to
conceive or who were already pregnant were included. After
completion of the PARA study, patients who gave permission to
be contacted for future research were approached to participate in
a follow-up study. In this follow-up study, patients filled in
questionnaires including inquiries on their reproductive
history, mode of conception for each pregnancy, visits to a
gynecologist, fertility assessments and fertility treatments.
These studies were approved by the Erasmus MC medical
ethics review board and was executed in compliance with the
Helsinki Declaration. All patients were above 18 years of age and
gave a written informed consent.
Data Collection
In the PARA study, home visits were performed before, three
times during and three times after pregnancy. The visit before
conception took place if the patient had a desire to conceive and
she and her partner did not use any contraceptives. If a patient did
not conceive within a year after the first visit, another visit took
place. At first visit, data on patient and disease characteristics
were collected, as well as medical and obstetric history. At each
visit, a physical exam was performed and disease activity was
scored using the 28-joint disease Activity Score with three
variables based on the C-reactive protein (CRP) level (DAS28-
CRP) according to literature (Fransen and van Riel, 2009). CRP
was determined using the Tina-Quant CRP Immunological Test
System (Roche Diagnostics, Almere, The Netherlands).
Additionally, blood samples were collected and serum was
stored at −80°C until use. IL-6 and TNFα serum levels were
measured using the IMMULITE 1000 (Siemens Healthcare
Diagnostics, Breda, The Netherlands). The intra-run/inter-run
mean ± variation coefficient was 105.6 ± 4.9%/87.67 ± 6.1% for
IL-6 and 105.6 ± 4.9%/89.5 ± 3.8% for TNFα, with a detection
threshold of 2.0 pg/ml. All cytokine levels are presented in pg/ml.
Cytokine levels represent the same data as previously described
by de Steenwinkel et al. (2013). In that study, the effect of
circulating maternal cytokines on birth weight of children was
studied at several time points during pregnancy. Measurements
were performed on serum taken at the preconception visit as an
estimate for cytokine levels during early pregnancy. In this paper,
preconception cytokine levels were re-analyzed in relation to time
to pregnancy. Therefore, the patients studied represent a
subgroup of the patients in the PARA-study: a pre-pregnancy
serum should be available and the patients should have given
birth during the follow-up period of the study.
Time to Pregnancy Calculation
Time to pregnancy was calculated as described by Brouwer et al.
(2015). At the preconception visit, the date the patient first began
trying to conceive actively was noted. Time to pregnancy was
calculated as the time elapsed between the first attempt to
conceive and the first day of the last menstrual period before
pregnancy. If the date of the last menstrual period was not known
by the patient, this date was calculated by subtracting 280 days
(40 weeks) from the due date based on sonographic examination
during early pregnancy. Because in several cases the couple
succeeded within the first month of trying to conceive, we
calculated a fictitious date by adding 28 days to the start of the
last menstrual period for all patients to avoid negative time to
pregnancy values.
Statistical Analysis
Descriptive statistics are presented as mean (SD), number
(percentage) or median [interquartile range (IQR)].
Characteristics of study population subgroups stratified by
time to pregnancy longer or shorter than 1 year were
compared using two-sample t tests, Wilcoxon rank-sum test
and two-sample tests of proportions as appropriate.
Differences between subgroups in levels of either IL-6 or
TNFα were analyzed using Wilcoxon rank-sum tests. Next,
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patients were stratified in either high or low IL-6 or TNFα based
on the median. Study population characteristic differences
between high and low cytokine level subgroups were analyzed
using two-sample t tests, Wilcoxon rank-sum test and two-
sample tests of proportions as appropriate. Differences in time
to pregnancy between high and low level cytokine categories were
studied using Kaplan–Meier survival curves. Significance between
curves was determined using a Gehan–Breslow–Wilcoxon test.
Furthermore, cox regression analyses were performed. First,
univariate cox regression analyses for time to pregnancy and
IL-6 or TNFαwere performed. This was followed by multivariable
cox regression analyses with variables DAS28-CRP and IL-6 or
TNFα. Next, multivariable cox regression analyses were executed
including variables age, disease activity, nulliparity, non-steroidal
anti-inflammatory drug (NSAID) use and prednisone use next to
IL-6 or TNFα. These variables were chosen in line with literature
(Brouwer et al., 2015). Since in literature some reproduction
disorders have been shown to be associated with increased IL-6
and TNFα levels, also a subgroup analysis was performed
excluding all patients who had been diagnosed with a disorder
leading to decreased fertility. In addition, those patients with a
partner with a known male cause for subfertility were excluded.
As CRP is strongly associated with IL-6 in literature (Tanaka
et al., 2014), it was investigated whether for daily clinical practice
IL-6 could be replaced by CRP in the analyses. For this purpose,
Spearman’s correlation of IL-6 and CRP was executed and the
same cox regression analyses were performed with CRP levels
instead of IL-6 levels to investigate if outcomes are similar.
Statistical analyses were two-tailed and results were considered




We included 61 out of 373 RA patients with a wish to conceive
from the PARA cohort. These patients had IL-6 and TNFα levels
determined at their preconception visit as well as clinical data
available. For three patients, IL-6 and TNFα levels were measured
at the second preconception visit, when they had been actively
trying to conceive for 1 year. The mean age (SD) of the study
population was 31.1 (3.5) years, duration of disease (IQR) was 6.0
(1.7–10.9) years and mean disease activity (DAS28-CRP) prior to
conception (SD) was 3.76 (0.97). Of all included patients, 31
(51%) were anti-citrullinated peptide antibodies (ACPA) positive,
35 (57%) were rheumatoid factor positive, 34 (56%) had erosive
disease, 35 (57%) were nulliparous and 19 (31%) had a time to
pregnancy >12 months. The following medication was used:
sulfasalazine by 19 (31%) patients, hydroxychloroquine by 2
(3%), prednisone by 26 (43%), azathioprine by 1 (2%) patient,
etanercept by 1 (2%) patient and gold therapy by 2 (3%) patients.
Subgroup analysis showed higher prednisone use in patients with
a time to pregnancy longer than 12 months. Described
characteristics can be found in Table 1.
Fourty six out of all 61 (75.4%) patients responded to the invite
for follow-up study for investigation of reproduction and fertility.
Of this population, eight patients (17.4%) were diagnosed with a
reproductive disorder: four patients out of 46 (8.7%) were
diagnosed with anovulation, 1 (2.2%) with endometriosis, 1
(2.2%) with early menopause, 1 (2.2%) with blockage of
fallopian tubes, 1 (2.2%) patient with a male factor influencing
fertility and 1 (2.2%) patient with anovulation as well as a male
factor.
TABLE 1 | Clinical and demographic features of the complete study population of 61 patients with rheumatoid arthritis and a wish to conceive, and subgroups divided by a
time to pregnancy (TTP) shorter or longer than 1 year.
Variable Study
population n = 61
TTP < 1 year n = 42 TTP > 1 year n = 19 p
Age in years—mean (SD) 31.1 (3.5) 31.1 (3.5) 31.2 (3.5) 0.913
Duration of disease in years—median (IQR) 6.0 (1.7–10.9) 5.5 (2.0–8.6) 9.0 (1.0–13.2) 0.544
DAS28-CRP—mean (SD) 3.76 (0.97) 3.74 (0.99) 3.80 (0.94) 0.833
ACPA positive—n (%) 31 (51) 19 (45) 12 (63) 0.241
RF positive—n (%) 35 (57) 22 (52) 13 (68) 0.195
Erosive disease—n (%) 34 (56) 22 (52) 12 (63) 0.433
Nulliparity—n (%) 35 (57) 24 (57) 11 (58) 0.956
Medication preconception—n (%)
None 21 (34) 17 (40) 4 (21) 0.139
NSAIDs 20 (33) 11 (26) 9 (47) 0.103
Prednisone 26 (43) 14 (33) 12 (63) 0.029*
Sulfasalazine 19 (31) 15 (36) 4 (21) 0.252
Hydroxychoroquine 2 (3) 1 (2.4) 1 (5.3) 0.558
Gold therapy 2 (3) 2 (4.8) 0 (0) 0.333
Azathioprine 1 (2) 0 (0) 1 (5.3) 0.134
Etanercept 1 (2) 1 (2.4) 0 (0) 0.498
ACPA, anti-citrullinated peptide antibodies; RF, rheumatoid factor; DAS28-CRP, 28-joint disease Activity Score with three variables based on the C-reactive protein level; NSAIDs, non-
steroidal anti-inflammatory drugs. * p < 0.05
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Serum Interleukin 6 and Tumor Necrosis
Factor Alpha Levels
In 14 out of 61 (23.0%) observations, IL-6 measurements were
below the detection limit. Therefore, for all measurements below
the detection limit, the IL-6 level was defined at the threshold
value of 2.0 pg/ml. IL-6 medians (IQR) were 3.44 (2.0–6.77) and
11.7 (2.67–21.4) pg/ml for patients with a time to pregnancy
<12 months (n  42) and patients with a time to pregnancy
>12 months (n  19), respectively. IL-6 levels were significantly
higher in patients with a time to pregnancy longer than 1 year
(p  0.016).
For TNFα, all measurements were above the detection limit.
TNFαmedian serum levels (IQR) were 9.76 (8.78–11.1) pg/ml for
patients with a time to pregnancy <12 months and 10.75
(8.72–13.0) pg/ml for patients with a time to pregnancy
>12 months. There was no significant difference between these
groups (p  0.33). Boxplots depicting IL-6 and TNFα distributions
categorized by time to pregnancy are shown in Figures 1A,B,
respectively.
Interleukin 6 and Time to Pregnancy
Patients were stratified in IL-6 low and IL-6 high categories
based on the median IL-6 level of the complete study population
(median  4.75 pg/ml). In the IL-6 high subgroup, disease
activity (DAS28-CRP) was higher, patients used more
NSAIDs and medication use in general was more frequent
than in the IL-6 low group (p  0.0005, p  0.0364 and p 
0.0022, respectively). Kaplan–Meier survival analysis (n  61)
shows a different time to pregnancy between the groups with
either high or low IL-6. The group with high IL-6 shows a
prolonged time to pregnancy compared to the group with low
levels of serum IL-6 (p  0.045). This survival curve is shown in
Figure 2.
IL-6 levels were logarithmically transformed before being
imputed in the regression analysis. Univariate cox regression
analysis showed that IL-6 is associated with time to pregnancy:
hazard ratio (HR) 0.68 (95% CI: 0.51–0.93, p  0.015). Cox
regression analysis with the variables IL-6 and DAS28-CRP
showed that higher IL-6 scores were associated with a reduced
chance of pregnancy, corrected for disease activity: HR for IL-6
0.66 (95% CI: 0.46–0.94, p  0.022). The multivariate cox
regression, with variables IL-6, age, disease activity, nulliparity,
NSAID use and prednisone use showed a significant association
between IL-6 and time to pregnancy with a HR 0.66 (95% CI:
0.43–0.99, p  0.044).
Furthermore, using the data from the follow-up study (n 
46), all patients with a diagnosis of a reproductive disorder that
could explain decreased fertility (n  8) were excluded in a
subgroup analysis. Seven out of eight exclusions belonged to the
subfertile group with a time to pregnancy longer than
12 months. Their median (IQR) IL-6 level was 7.86
(1.34–27.35) pg/ml. Univariate analysis of IL-6 (n  38)
showed a significant association of IL-6 levels with time to
FIGURE 1 | Boxplots showing interleukin 6 (IL-6) and tumor necrosis factor alpha distributions with median and interquartile range stratified by time to pregnancy
(A,B, respectively). The y-axis represents serum cytokine levels of Rheumatoid Arthritis patients with a wish to conceive (pg/ml), the x-axis shows patient groups stratified
for time to pregnancy. IL-6 levels were statistically significant higher in patients with a time to pregnancy >12 months compared to patients with a time to pregnancy
<12 months (p  0.016) (A). *  p < 0.05.
FIGURE 2 | Kaplan-Meier survival curves showing time to pregnancy in
interleukin 6 (IL-6) high (n  31) vs. IL-6 low (n  30) patients. The y-axis shows
the proportion of patients who are not yet pregnant, the x-axis shows the
analysis time (years). The survival curve shows that time to pregnancy is
longer for patients with high levels of IL-6 (p  0.045).
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pregnancy: HR 0.69 (95% CI: 0.48–0.99, p  0.046). Next,
multivariate analysis with variables IL-6, age, disease activity,
nulliparity, NSAID use and prednisone in relation to time to
pregnancy was performed on the same subgroup (n  38) and
showed a significant association between IL-6 and time to
pregnancy: HR 0.54 (95% CI: 0.32–0.92, p  0.023).
Tumor Necrosis Factor Alpha and Time to
Pregnancy
After stratification of patients in TNFα low and high categories
by the median of 9.76 pg/ml, patients in the TNFα high
subgroup had longer duration of disease (p  0.0182).
Survival analysis for TNFα stratified by high and low serum
levels did not show the same pattern as IL-6. Kaplan Meier
survival (n  61) showed that having high or low serum TNFα
did not have an effect on time to pregnancy (p  0.62). Levels of
TNFα were logarithmically transformed before being imputed
into the models. Univariate cox regression analysis showed that
TNFα is not associated with time to pregnancy: HR 1.41 (95%
CI: 0.88–2.24, p  0.15). Cox regression analysis with the
variables TNFα and DAS28-CRP and analysis with variables
TNFα, age, disease activity, nulliparity, NSAID use and
prednisone use did not show an effect of TNFα on the
probability of pregnancy: HR 1.41 (95% CI: 0.90–2.25, p 
0.14) and HR 1.34 (95% CI: 0.75–2.39, p  0.33),
respectively. Univariate analysis of the subgroup excluding all
patients with a reproductive disorder or a male factor [median
(IQR) TNFα level of excluded patients: 8.62 (8.10–9.29) pg/ml]
that could explain decreased fertility (n  38) showed no
association of TNFα with time to pregnancy: HR 1.12 (95%
CI: 0.63–1.98, p  0.69). Lastly, multivariate analysis on the same
subgroup including TNFα, age, disease activity, nulliparity,
NSAID use and prednisone in relation to time to pregnancy
did not show an association between TNFα levels and time to
pregnancy: HR 1.41 (95% CI: 0.71–2.78, p  0.31).
C-Reactive Protein and Time to Pregnancy
IL-6 and CRP levels are strongly correlated in our study
population (Spearman’s rank correlation, rs  0.71). CRP
values were log transformed for cox regression analyses.
Univariate analysis of CRP in relation to time to pregnancy
showed a significant effect on time to pregnancy: HR 0.81 (95%
CI: 0.65–1.00, p  0.048). Multivariate cox regression analysis
with the variables CRP and DAS28-CRP and analysis with
variables CRP, age, disease activity, nulliparity, NSAID use
and prednisone use both showed an association between
CRP levels and time to pregnancy: HR 0.76 (95% CI:
0.59–0.99, p  0.044) and HR 0.76 (95% CI: 0.59–0.98, p 
0.036), respectively. No significant association between CRP
and time to pregnancy was found in the subgroup analyses
excluding patients with a reproductive disorder or a male factor
that could explain decreased fertility (n  38) (univariate
analysis HR 0.83 (95% CI: 0.64–1.06, p  0.137); multivariate
analysis with variables CRP, age, disease activity, nulliparity,
NSAID use and prednisone use HR 0.74 (95% CI: 0.53–1.03, p 
0.075).
DISCUSSION
Our study is the first to evaluate IL-6 and TNFα as potential
influencing factors of subfertility in RA patients. We showed that
IL-6 is increased in RA patients with a time to pregnancy longer
than 12 months. High IL-6 levels are associated with a prolonged
time to pregnancy, even when corrected for potential
confounders, like disease activity, medication and diagnosis of
reproductive disorders, in a large cohort of RA patients with a
wish to conceive. For TNFα levels, no association with fertility
was found.
This report, combined with previous studies on the link
between IL-6 and reproductive disorders and fertility (Demir
et al., 2009; Peng et al., 2016; Wang F. et al., 2018; Wang X. M.
et al., 2018), provides an indication that high levels of circulating
IL-6 hamper fertility. However, the biological mechanisms
behind this phenomenon are not known. A possible
explanation could be the role of IL-6 in T cell differentiation.
IL-6 is a known influencer thereof, driving follicular helper T cell
differentiation and enabling T helper 17 cell over regulatory T cell
differentiation (Schinnerling et al., 2017). A disturbed T helper 17
and regulatory T cell balance has been associated with fertility and
pregnancy disorders through lack of immunologic tolerance,
which is pivotal for implantation and pregnancy maintenance
(Jasper et al., 2006; Figueiredo and Schumacher, 2016).
Despite the association between IL-6 and fertility, IL-6 might
not directly be involved in subfertility pathogenesis. It is possible
IL-6 is a proxy for something else, such as a disease related factor.
For example, IL-6 levels are known to be associated with disease
activity (Madhok et al., 1993). Therefore, in our analyses, a
correction was made for disease activity score and other
possible confounders based on literature. Another possibility is
that IL-6 could be a proxy for other factors in the same
inflammatory cascade. Fertility immunology is an upcoming
field and exact mechanisms surrounding conception and
implantation, certainly within RA patients, are yet to be
resolved. More research on fertility biology is needed to
elucidate the exact role of IL-6 as well as T helper subset
balance in this matter.
Within the subgroup with a time to pregnancy shorter than
1 year, some patients with high IL-6 levels are present
(Figure 1A). However, since there is only one cytokine
measurement available representing the complete
preconception time period, it is unclear if cytokines levels
were stable in these patients. A possible explanation for these
outliers, next to chance, is temporarily high IL-6 levels in the
context of infection.
Since decreased fertility is an important issue in women with
RA during reproductive age, treatment of patients with a wish to
conceive should not only target the immune system in a way that
controls maternal disease activity, but also take into account how
therapy could affect fertility. Based on this study, the IL-6
pathway might be considered as a therapeutic target in
patients with RA and a wish to conceive. Therapies directed at
the IL-6 receptor, such as tocilizumab, could be a promising
option for those patients. However, for these therapeutic agents,
little is known about drug safety during pregnancy. Due to lack of
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safety data, current guidelines state that tocilizumab should be
stopped in RA patients with a wish to conceive (Götestam
Skorpen et al., 2016). Small studies report no adverse
pregnancy outcomes in patients exposed to tocilizumab, but
numbers are too limited to be conclusive on the matter
(Nakajima et al., 2016). Consequently, to this date, tocilizumab
is not an appropriate therapeutic option for RA patients in the
time period before pregnancy, but could be seriously considered
in the future, when there is more clarity on teratogenicity.
Meanwhile, TNFα inhibition (TNFi) is a widely used treatment
option for RA and current guidelines state that TNFα inhibitors
are appropriate therapeutic agents for patients with a wish to
conceive (Götestam Skorpen et al., 2016; Sammaritano et al.,
2020). Although our analyses show no correlation of circulating
TNFα-levels with fertility, TNFα is a driver of IL-6 and use of
TNFi has been shown to decrease circulating IL-6 levels (Charles
et al., 1999). Moreover, TNFi has been reported to expand
regulatory T cells (Nguyen and Ehrenstein, 2016). Therefore,
treatment with TNFi could be a potential option to increase
fertility in women with active RA. In a small study, it was indeed
reported that TNFi decreases time to pregnancy in RA patients
with a wish to conceive (Shimada et al., 2019). Potential effects of
TNFi on pregnancy outcomes should be considered. Increased
risks associated with TNFi of preterm birth, caesarean section
and small for gestational age children have been previously
reported (Bröms et al., 2020). However, given the study design
and the fact that high disease activity is known to negatively
influence pregnancy outcomes (Smeele and Dolhain, 2019), these
effects might not be drug-derived, but due to confounding by
indication.
Given the fact that IL-6 serum levels are correlated to disease
activity (Madhok et al., 1993), as also displayed by our results,
effective treatment of RA patients with other DMARDs such as
sulfasalazine presumably decrease IL-6 levels and possibly
enhance fertility as well. More evidence on the effect of
different DMARDs on fertility from large cohort studies is
needed to confirm this effect and to further elucidate the
mechanisms behind it.
In daily clinical practice, IL-6 levels are not routinely
measured. This makes the possibility to use IL-6 levels as a
potential biomarker for fertility in RA patients with a wish to
conceive less practical. However, IL-6 is a strong driver of CRP
and high CRP levels are predictive for high IL-6 (Tanaka et al.,
2014). For that reason all analyses were performed with CRP
instead of IL-6 and for the main analyses similar results were
found. Therefore, in daily practice, when no IL-6 levels are
available, also CRP is a potential indicator for time to
pregnancy in RA-patients with a wish to conceive. Analysis of
a larger patient population would give more insight into the value
of CRP as a clinical biomarker for fertility.
No association of TNFα levels with fertility was found. This
raises the question whether our study is adequately powered to
show the potential influence of TNFα on fertility. A post-hoc
power calculation shows that, based on the data in this study, over
1,300 patient inclusions are needed to demonstrate a statistically
significant difference. This is an indication that a potential
difference in TNFα levels is probably not clinically relevant.
Previous reports have shown the PARA cohort to be a
representative study population. However, cytokine levels were
only determined in samples of patients who had serum from the
preconception time point available and who had eventually
successfully achieved pregnancy and delivered a child, because of
previous research purposes (de Steenwinkel et al., 2013). This led to
inclusion of 61 out of 373 total patients in the PARA cohort.
Nevertheless, we do not expect that this causes the results to be
invalid. Our study population is skewed to a relatively more fertile
subgroup of the complete PARA cohort and the results still show an
association between IL-6 and time to pregnancy. Although it is
presumable that IL-6 levels are high in infertile RA patients as well,
this group is not represented in the study population and should be
further investigated.
In conclusion, this study shows that high IL-6 levels, but not
TNFα, are associatedwith decreased fertility in womenwith RA and a
wish to conceive. This finding provides a rationale to therapeutically
target the IL-6 pathway in the time period before pregnancy.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by Erasmus MC medical ethics review board. The
patients/participants provided their written informed consent
to participate in this study.
AUTHOR CONTRIBUTIONS
MB and HS drafted the work, analyzed the data and wrote the
manuscript. EL and RD critically revised the text and figures. All
authors approved the final manuscript for publication.
FUNDING
This work was supported by the Dutch Arthritis Foundation
(ReumaNederland) (project numbers: LLP-26 and NR 19-2-401)
and UCB Pharma. The funders were not involved in the study
design, collection, analysis, interpretation of data, the writing of
this article or the decision to submit it for publication.
ACKNOWLEDGMENTS
The authors are grateful to all patients who participated in the
PARA study. Additionally, they thank Yaël de Man, Fleur van de
Geijn, Esther Gasthuis, Florentien de Steenwinkel, Jenny Brouwer
and all laboratory workers and research assistants for their
contribution to the data collection.
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 6048666
Bongenaar et al. Rheumatoid Arthritis, IL-6 and Fertility
REFERENCES
Arnett, F. C., Edworthy, S. M., Bloch, D. A., McShane, D. J., Fries, J. F., Cooper, N.
S., et al. (1988). The American Rheumatism Association 1987 revised criteria
for the classification of rheumatoid arthritis. Arthritis Rheum. 31 (3), 315–324.
doi:10.1002/art.1780310302
Bröms, G., Kieler, H., Ekbom, A., Gissler, M., Hellgren, K., Lahesmaa-Korpinen, A.
M., et al. (2020). Anti-TNF treatment during pregnancy and birth outcomes: a
population-based study from Denmark, Finland, and Sweden.
Pharmacoepidemiol. Drug Saf. 29 (3), 316–327. doi:10.1002/pds.4930
Brouwer, J., Hazes, J. M., Laven, J. S., and Dolhain, R. J. (2015). Fertility in women
with rheumatoid arthritis: influence of disease activity and medication. Ann.
Rheum. Dis. 74 (10), 1836–1841. doi:10.1136/annrheumdis-2014-205383
Charles, P., Elliott, M. J., Davis, D., Potter, A., Kalden, J. R., Antoni, C., et al. (1999).
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following
anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163 (3),
1521–1528.
deMan, Y. A., Dolhain, R. J., van de Geijn, F. E.,Willemsen, S. P., andHazes, J. M. (2008).
Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide
prospective study. Arthritis Rheum. 59 (9), 1241–1248. doi:10.1002/art.24003
de Steenwinkel, F. D., Hokken-Koelega, A. C., de Man, Y. A., de Rijke, Y. B., de
Ridder, M. A., Hazes, J. M., et al. (2013). Circulating maternal cytokines
influence fetal growth in pregnant women with rheumatoid arthritis. Ann.
Rheum. Dis. 72 (12), 1995–2001. doi:10.1136/annrheumdis-2012-202539
Demir, B., Guven, S., Guven, E. S., Atamer, Y., and Gul, T. (2009). Serum IL-6 level
may have role in the pathophysiology of unexplained infertility. Am. J. Reprod.
Immunol. 62 (4), 261–267. doi:10.1111/j.1600-0897.2009.00734.x
Ebejer, K., and Calleja-Agius, J. (2013). The role of cytokines in polycystic ovarian
syndrome. Gynecol. Endocrinol. 29 (6), 536–540. doi:10.3109/09513590.2012.
760195
Figueiredo, A. S., and Schumacher, A. (2016). The T helper type 17/regulatory T cell
paradigm in pregnancy. Immunology 148 (1), 13–21. doi:10.1111/imm.12595
Fransen, J., and van Riel, P. L. (2009). The disease activity score and the EULAR
response criteria. Rheum. Dis. Clin. N. Am. 35 (4), 745–viii. doi:10.1016/j.rdc.
2009.10.001
Götestam Skorpen, C., Hoeltzenbein, M., Tincani, A., Fischer-Betz, R., Elefant, E.,
Chambers, C., et al. (2016). The EULAR points to consider for use of
antirheumatic drugs before pregnancy, and during pregnancy and lactation.
Ann. Rheum. Dis. 75 (5), 795–810. doi:10.1136/annrheumdis-2015-208840
Iwabe, T., Harada, T., and Terakawa, N. (2002). Role of cytokines in endometriosis-
associated infertility. Gynecol. Obstet. Invest. 53 (Suppl. 1), 19–25.
Jasper, M. J., Tremellen, K. P., and Robertson, S. A. (2006). Primary unexplained
infertility is associated with reduced expression of the T-regulatory cell
transcription factor Foxp3 in endometrial tissue. Mol. Hum. Reprod. 12 (5),
301–308. doi:10.1093/molehr/gal032
Kang, S., Tanaka, T., Narazaki, M., and Kishimoto, T. (2019). Targeting
interleukin-6 signaling in clinic. Immunity 50 (4), 1007–1023. doi:10.1016/j.
immuni.2019.03.026
Madhok, R., Crilly, A., Watson, J., and Capell, H. A. (1993). Serum interleukin 6
levels in rheumatoid arthritis: correlations with clinical and laboratory indices
of disease activity. Ann. Rheum. Dis. 52 (3), 232–234. doi:10.1136/ard.52.3.232
Markert, U. R., Morales-Prieto, D. M., and Fitzgerald, J. S. (2011). Understanding the
link between the IL-6 cytokine family and pregnancy: implications for future
therapeutics. Expet Rev. Clin. Immunol. 7 (5), 603–609. doi:10.1586/eci.11.60
McInnes, I. B., and Schett, G. (2017). Pathogenetic insights from the treatment of
rheumatoid arthritis. Lancet 389 (10086), 2328–2337. doi:10.1016/S0140-
6736(17)31472-1
Nakajima, K., Watanabe, O., Mochizuki, M., Nakasone, A., Ishizuka, N., and
Murashima, A. (2016). Pregnancy outcomes after exposure to tocilizumab: a
retrospective analysis of 61 patients in Japan.Mod. Rheumatol. 26 (5), 667–671.
doi:10.3109/14397595.2016.1147405
Nguyen, D. X., and Ehrenstein, M. R. (2016). Anti-TNF drives regulatory T cell
expansion by paradoxically promoting membrane TNF-TNF-RII binding in
rheumatoid arthritis. J. Exp. Med. 213 (7), 1241–1253. doi:10.1084/jem.
20151255
Peng, Z., Sun, Y., Lv, X., Zhang, H., Liu, C., and Dai, S. (2016). Interleukin-6
levels in women with polycystic ovary syndrome: a systematic review and
meta-analysis. PLoS One 11 (2), e0148531. doi:10.1371/journal.pone.
0148531
Sammaritano, L. R., Bermas, B. L., Chakravarty, E. E., Chambers, C., Clowse, M. E.
B., Lockshin, M. D., et al. (2020). American College of Rheumatology guideline
for the management of reproductive health in rheumatic and musculoskeletal
diseases. Arthritis Rheumatol. 72 (4), 529–556.
Schinnerling, K., Aguillón, J. C., Catalán, D., and Soto, L. (2017). The role of
interleukin-6 signalling and its therapeutic blockage in skewing the T cell
balance in rheumatoid arthritis. Clin. Exp. Immunol. 189 (1), 12–20. doi:10.
1111/cei.12966
Shimada, H., Kameda, T., Kanenishi, K., Miyatake, N., Nakashima, S., Wakiya, R.,
et al. (2019). Effect of biologic disease-modifying anti-rheumatic drugs for
patients with rheumatoid arthritis who hope to become mothers. Clin.
Rheumatol. 38 (5), 1453–1458. doi:10.1007/s10067-019-04450-3
Smeele, H. T. W., and Dolhain, R. J. E. M. (2019). Current perspectives on fertility,
pregnancy and childbirth in patients with rheumatoid arthritis. Semin. Arthritis
Rheum. 49 (3S), S32–S5. doi:10.1016/j.semarthrit.2019.09.010
Smolen, J. S., Aletaha, D., and McInnes, I. B. (2016). Rheumatoid arthritis. Lancet
388 (10055), 2023–2038. doi:10.1016/S0140-6736(16)30173-8
Tanaka, T., Narazaki, M., and Kishimoto, T. (2014). IL-6 in inflammation,
immunity, and disease. Cold Spring Harb. Perspect. Biol. 6 (10), a016295.
doi:10.1101/cshperspect.a016295
Taylor, P. C., and Feldmann, M. (2009). Anti-TNF biologic agents: still the therapy
of choice for rheumatoid arthritis.Nat. Rev. Rheumatol. 5 (10), 578–582. doi:10.
1038/nrrheum.2009.181
Wang, F., Wang, H., Jin, D., and Zhang, Y. (2018). Serum miR-17, IL-4, and IL-6
levels for diagnosis of endometriosis. Medicine 97 (24), e10853. doi:10.1097/
MD.0000000000010853
Wang, X. M., Ma, Z. Y., and Song, N. (2018). Inflammatory cytokines IL-6, IL-10,
IL-13, TNF-α and peritoneal fluid flora were associated with infertility in
patients with endometriosis. Eur. Rev. Med. Pharmacol. Sci. 22 (9), 2513–2518.
doi:10.26355/eurrev_201805_14899
Wu, M. Y., and Ho, H. N. (2003). The role of cytokines in endometriosis. Am.
J. Reprod. Immunol. 49 (5), 285–296. doi:10.1034/j.1600-0897.2003.01207.x
Yoshida, Y., and Tanaka, T. (2014). Interleukin 6 and rheumatoid arthritis.
BioMed. Res. Int. 2014, 698313. doi:10.1155/2014/698313
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Bongenaar, Smeele, Lubberts and Dolhain. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Pharmacology | www.frontiersin.org December 2020 | Volume 11 | Article 6048667
Bongenaar et al. Rheumatoid Arthritis, IL-6 and Fertility
